Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
JOINN Laboratories (China) Co., Ltd. Class H ( (HK:6127) ) has provided an announcement.
JOINN Laboratories (China) Co., Ltd. has issued a profit warning for 2025, flagging that revenue is expected to fall by about 13.9% to 22.1% year on year to roughly RMB1.57 billion–RMB1.74 billion, reflecting weaker performance in its core laboratory services and related business, which is projected to generate a significant loss. Despite the revenue decline, the company anticipates a sharp rebound in profitability, with net profit attributable to shareholders expected to surge by about 214%–371% and adjusted net profit by roughly 945%–1,468%, mainly driven by large gains from changes in the fair value of its biological assets, underscoring a growing reliance on non-operating valuation effects rather than underlying operational strength.
The most recent analyst rating on (HK:6127) stock is a Hold with a HK$27.00 price target. To see the full list of analyst forecasts on JOINN Laboratories (China) Co., Ltd. Class H stock, see the HK:6127 Stock Forecast page.
More about JOINN Laboratories (China) Co., Ltd. Class H
JOINN Laboratories (China) Co., Ltd. is a China-based contract research organization focused on providing preclinical and other laboratory services to pharmaceutical and biotechnology clients. The group’s business includes laboratory services and related operations, and it also holds biological assets whose fair value changes can materially affect reported earnings.
Average Trading Volume: 5,307,731
Technical Sentiment Signal: Buy
Current Market Cap: HK$32.68B
For detailed information about 6127 stock, go to TipRanks’ Stock Analysis page.